Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor–Mutant Lung Cancer

The phase 3 ADAURA trial, which tested adjuvant osimertinib mesylate vs placebo in patients with resected stage IB through IIIA non–small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR), was a surprise addition to the plenary presentation at the recent annual meeting of the American Society of Clinical Oncology. The trial was unexpectedly unblinded in April 2020 at the recommendation of the Independent Data Monitoring Committee when an interim analysis showed it had met its primary end point of improving disease-free survival (DFS).¹